Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Friday, July 31, 2026.
Reported quarterly profit margin; no daily interpolation. Q1 FY2027 (2026-07-31): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
0.00%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 794 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Alzamend Neuro Inc
Market Cap
$5.23M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.23M
Net Profit Margin
-4011.86%
TTM Avg
-2005.93%
3Y Avg
-2671.67%
5Y Avg
-1781.12%
Market Cap
$5.18M
Net Profit Margin
-106.78%
TTM Avg
-43.08%
3Y Avg
-12.30%
5Y Avg
-12.30%
Market Cap
$5.16M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.30M
Net Profit Margin
-612568.11%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.24M
Net Profit Margin
-294.91%
TTM Avg
-320.57%
3Y Avg
-453.36%
5Y Avg
-361.46%
Market Cap
$5.38M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1379.84%
5Y Avg
-7344.76%
Market Cap
$5.41M
Net Profit Margin
0.00%
TTM Avg
-61.23%
3Y Avg
-156.55%
5Y Avg
-194.88%
Market Cap
$5.04M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1794.91%
5Y Avg
-2605.04%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alzamend Neuro Inc (ALZN) | $5.23M | 0.00% | 0.00% | 0.00% | 0.00% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | -4011.86% | -2005.93% | -2671.67% | -1781.12% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.18M | -106.78% | -43.08% | -12.30% | -12.30% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.16M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.30M | -612568.11% | 0.00% | 0.00% | 0.00% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | -294.91% | -320.57% | -453.36% | -361.46% |
| Soligenix, Inc. (SNGX)vs › | $5.38M | 0.00% | 0.00% | -1379.84% | -7344.76% |
| Pulmatrix, Inc. (PULM)vs › | $5.41M | 0.00% | -61.23% | -156.55% | -194.88% |
| Imunon, Inc. (IMNN)vs › | $5.04M | 0.00% | 0.00% | -1794.91% | -2605.04% |
| Xenetic Biosciences, Inc. (XBIO)vs › | $5.01M | -75.90% | -124.23% | -198.78% | -629.10% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-07-31 | 0.00% |
| 2026-04-30 | 0.00% |
| 2026-01-31 | 0.00% |
| 2025-10-31 | 0.00% |
| 2025-07-31 | 0.00% |
| 2025-04-30 | 0.00% |
| 2025-01-31 | 0.00% |
| 2024-10-31 | 0.00% |
| 2024-07-31 | 0.00% |
| 2024-04-30 | 0.00% |
| 2024-01-31 | 0.00% |
| 2023-10-31 | 0.00% |
| 2023-07-31 | 0.00% |
| 2023-04-30 | 0.00% |
| 2023-01-31 | 0.00% |
| 2022-10-31 | 0.00% |
| 2022-07-31 | 0.00% |
| 2022-04-30 | 0.00% |
| 2022-01-31 | 0.00% |
| 2021-10-31 | 0.00% |
| 2021-07-31 | 0.00% |
| 2021-04-30 | 0.00% |
| 2021-01-31 | 0.00% |
| 2020-10-31 | 0.00% |
| 2020-07-31 | 0.00% |
| 2020-04-30 | 0.00% |
| 2020-01-31 | 0.00% |
| 2019-10-31 | 0.00% |
| 2019-07-31 | 0.00% |
| 2019-04-30 | 0.00% |
| 2019-01-31 | 0.00% |
| 2018-10-31 | 0.00% |
| 2018-07-31 | 0.00% |
| 2018-04-30 | 0.00% |
| 2018-01-31 | 0.00% |
| 2017-10-31 | 0.00% |
| 2017-07-31 | 0.00% |
| 2017-04-30 | -337.08% |
| 2017-01-31 | -337.08% |
| 2016-10-31 | 0.00% |
| 2016-07-31 | 0.00% |
